Home Newsfeeds Oppenheimer Downgrades Tesla to Perform

Oppenheimer Downgrades Tesla to Perform

Oppenheimer analyst Colin Rusch downgrades Tesla (NASDAQ:TSLA) from Outperform to Perform.

byBenzinga Newsdesk

December 19, 2022

1 minute read

Oppenheimer analyst Colin Rusch downgrades Tesla (NASDAQ:TSLA) from Outperform to Perform.

Costco And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

By Lisa Levin

September 27, 5:55 AM

U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

CDT

JanOne To Present Prior Phase II Data On Diabetic Neuropathy At The Ohio Society Of Interventional Pain Physicians Annual Meeting

By Happy Mohamed

August 18, 12:49 PM

JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS, Aug. 18, 2023 /PRNewswire/ -- JanOne (NASDAQ:JAN), a biopharmaceutical

JAN

SVB Leerink Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $75

By Benzinga Newsdesk

December 14, 5:00 AM

SVB Leerink analyst Andrew Berens maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and lowers the price target from $85 to $75.

MRTX

Femasys’ FemCerv Endocervical Tissue Sampler For Cervical Cancer Diagnosis Receives Product Approval In Canada

By Benzinga Newsdesk

May 3, 8:40 AM

- FemCerv® is the first endocervical tissue sampler designed to collect and contain a comprehensive sample to maximize quality and quantity - ATLANTA, May 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc.

FEMY

Oppenheimer Downgrades Tesla to Perform

Related Posts

Costco And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

JanOne To Present Prior Phase II Data On Diabetic Neuropathy At The Ohio Society Of Interventional Pain Physicians Annual Meeting

SVB Leerink Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $75

Femasys’ FemCerv Endocervical Tissue Sampler For Cervical Cancer Diagnosis Receives Product Approval In Canada